PSC as a chronic cholestatic liver disease is characterized by long-standing and progressive inflammation and fibrosis around the bile ducts. This disease can lead to liver cirrhosis and may be superimposed by bile duct epithelial changes (
6).
There are controversial reports about the multistep carcinogenesis in PSC, i.e. the sequential steps of inflammation/hyperplasia/metaplasia/dysplasia in the course of development of cholangiocarcinoma in the patients with PSC (
4,
7-
10).
Diagnosis of these lesions as precursors of malignancy in PSC livers can be difficult. Imaging techniques, although have essential role in diagnosis of CCA, are not helpful to detect flat precancerous epithelial lesions. Thus, diagnosis should be based on pathological and laboratory information (
10).
Very few studies have been performed to find the incidence of biliary intraepithelial neoplasia (BilIN) as precursor lesions of invasive adenocarcinoma in the biliary tracts (cholangiocarcinoma); most of the previous studies on PSC-associated bile duct epithelial dysplasia have been in the form of case reports and there are only a few case series (
7-
16).
In this study conducted on 80 PSC formalin-fixed explanted livers during 2 years (2014 - 2015), there were 43(53.75%) PSC cases with different types of bile duct epithelial metaplasia. Pyloric type metaplasia was the most frequent type of metaplasia, which has been found in 29 cases (35%) of PSC, followed by mucinous metaplasia (which is classified as BilIN-1) with 10.8% prevalence. This finding is compatible with that reported by Abraham et al. in 2010. They studied 30 explanted livers with PSC and found mucinous metaplasia and pyloric metaplasia as the two most frequent epithelial changes in 77% and 73% of livers, respectively (
4). In 2 out of 9 patients (22%) with BilIN-1, we also observed intestinal metaplasia.
In our study, there were 2 cases with unusual metaplastic changes such as squamous (in one case with 24 months duration of disease) and osteoid (in one case with 48 months duration). Abraham et al. noticed squamous metaplasia in 3% of their cases; however, osteoid metaplasia was not reported in the previous studies. On the other hand, we did not have any case with pancreatic acinar metaplasia, which has been reported in 10% of the previously examined cases (
4).
Our data showed frequent metaplastic changes in the bile duct epithelium of PSC livers but dysplastic changes (low and high) were not found.
In PSC group, Bergquist et al. found 2 cases out of 16 (13%) (
8), Ludwig et al. found 1 case of papillary hyperplasia among 60 (3%) (
17), Fleming et al. found no case (
10) and Katabi and Albores-Saavedra found only 2 (4%) cases with dysplastic changes (
18). However, there were also studies with higher frequencies of bile duct epithelial changes (
4). Abraham et al. reported 36% dysplasia in their study population. It should be noted that Abraham et al. worked on explanted livers and took more sections especially from large bile ducts (
4); but other studies used needle biopsy or if they worked on whole livers, they had limited number of sections (
8,
17,
18). In this study, we worked on whole explanted liver with thorough sampling (at least 14 from peripheral and central bile ducts); however, no dysplasia was found. (
Table 3 shows the frequencies of bile duct epithelial changes in different studies). According to the previous studies conducted at our center, compared to other centers in the Western parts of the world, the incidence of CCA in our PSC cases is low to intermediate. This means that the incidence of CCA has been reported in up to 36.5% of PSC patients, while it has been 8.8% at our center (
6). The absence of any bile duct epithelial dysplasia in 80 PSC livers with mean disease duration of around 4 years is compatible with low incidence of CCA in our PSC cases.
Patients with PSC usually are followed up by imaging techniques and regular monitoring of tumor markers in addition to other laboratory tests to diagnose the development of CCA as soon as possible. However, many cases with CCA are detected late in their course with poor prognosis. In early stages, cytology/biopsy and imaging studies are usually negative (
21).
Diagnosis of PSC with bile duct epithelial metaplasia and dysplasia as early precursors of malignancy can be important to increase patients’ survival. In our study population, there were no significant demographic differences between PSC cases and those PSC cases with BilIN; however, bilirubin was significantly higher in the former group. In the study performed by Haseeb et al. the level of bilirubin was introduced as a predictor of CCA; however, there is no report about the level of bilirubin and development of bile duct epithelial damage in PSC patients (
22).
In our study group consisted of 80 patients with PSC, most of the tumor markers were the same in the livers with and without BilIN, however, CA19-9 was significantly higher in the former group. Although this relationship has not been investigated before, the level of CA19-9 has been recognized as a good predictor of CCA in the patients with PSC (
21).